Celiac Disease Drugs Market Report 2026, Trends, Forecast

What Is The Present Market Size Of The Celiac Disease Treatment Market, And At What Annual Growth Rate Is It Expanding?
The celiac disease treatment market size has grown strongly in recent years. It will grow from $0.66 billion in 2025 to $0.72 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to limited pharmacological treatment options, reliance on gluten-free diet management, increasing diagnosis rates, rising awareness of autoimmune disorders, growth in diagnostic testing availability.

The celiac disease treatment market size is expected to see strong growth in the next few years. It will grow to $1.03 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to development of non-dietary therapeutic options, expansion of enzyme and immunotherapy pipelines, rising global prevalence of celiac disease, improved diagnostic accuracy, increased healthcare spending on chronic autoimmune diseases. Major trends in the forecast period include increasing adoption of gluten-free dietary management, growing development of enzyme-based therapies, rising focus on early diagnosis and screening, expansion of nutritional supplement-based treatments, increasing patient awareness and disease education.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24186&type=smp

What Fundamental Drivers Are Expected To Boost The Celiac Disease Treatment Market Throughout The Forecast Period?
The rise in the prevalence of diabetes is expected to propel the growth of the celiac disease treatment market going forward. Diabetes is a chronic medical condition where the body is unable to regulate blood sugar or glucose levels properly. The increasing prevalence of diabetes is due to shared dietary management needs, as both diabetes and celiac disease require careful control of food intake to manage blood sugar levels and prevent complications. Celiac disease treatment aids diabetes by promoting a gluten-free diet, which can help improve overall digestive health and nutrient absorption. It supports better blood sugar control and reduces complications in individuals managing both conditions. For instance, in June 2024, according to the National Health Service, a UK-based government department, around 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rise in the prevalence of diabetes is driving the growth of the celiac disease treatment market.

What Are The Key Segmentation Components That Define The Structure Of The Celiac Disease Treatment Market?
The celiac disease treatment market covered in this report is segmented –

1) By Treatment Type: Vitamins And Minerals, Gluten Degrading Enzymes, Symptomatic Treatment, Other Treatments
2) By Diagnosis: Serological Tests, Genetic Testing, Biopsy
3) By Distribution Channel: Hospitals, Research Centres, Clinics, Other Distribution Channels

Subsegments:
1) By Vitamins and Minerals: Iron Supplements, Calcium Supplements, Vitamin D, Vitamin B12, Multivitamins
2) By Gluten Degrading Enzymes: Endopeptidases, Exopeptidases, Combination Enzyme Formulations
3) By Symptomatic Treatment: Antidiarrheal Medications, Antidepressants, Anti-inflammatory Drugs, Immunosuppressive Agents
4) By Other Treatments: Probiotics, Immunotherapy, Experimental Therapies

Which Trends Are Expected To Steer The Evolution Of The Celiac Disease Treatment Market?
Major companies operating in the celiac disease treatment market are focusing on developing oral therapies, such as small molecule therapies, to provide targeted relief by blocking immune responses to gluten, improving patient adherence, and offering alternatives to strict gluten-free diets. Small molecule therapies are tiny drugs that enter cells easily to target and treat disease-causing proteins or enzymes. For instance, in February 2025, Immunic Inc., a US-based biotechnology company, launched IMU-856. IMU-856 is a small molecule that increases endogenous glucagon-like peptide-1 (GLP-1) levels, which helps improve intestinal barrier function in celiac disease patients. It also enhance nutrient absorption and alleviate symptoms without suppressing immune activity.

Who Are The Standout Companies Known For Innovation In The Celiac Disease Treatment Market?
Major companies operating in the celiac disease treatment market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceuticals Company Ltd., Amgen Inc., General Mills Inc., Viatris Inc., Teva Pharmaceutical Inc., Nestlé Health Science, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals Inc., Glenmark Pharmaceuticals Company Ltd., West-Ward Pharmaceuticals Company Ltd, Innovate Biopharmaceutical, Acto Biosciences, ImmunogenX

Get Your In-Depth Celiac Disease Treatment Market Report Now:
https://www.thebusinessresearchcompany.com/report/celiac-disease-treatment-global-market-report

Which Geographical Region Is Projected To Lead The Celiac Disease Treatment Market Throughout The Forecast Period?
North America was the largest region in the celiac disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company